En español
NIDA

Menu

NIDA Notes Articles: HIV or AIDS

NIDA Notes Category Graphic

NIDA Recognizes Developer of a New Business Model for Science

November 2011
Dr. Redonna K. Chandler of NIDA receives the Institute's 2011 Innovator Award for developing a method that fosters collaboration and data sharing on various studies of HIV in criminal justice populations.

NIDA Notes Category Graphic

Women and Sex/Gender Differences Research Program

April 2012
NIDA’s Women and Sex/Gender Differences Research Program focuses on gender-specific addiction risk factors and treatment needs.

NIDA Notes Category Graphic

Antiretroviral Treatment Reduces Spread of HIV Among Injection Drug Users

April 2012
Expanded use of antiretroviral therapy in British Columbia reduced the spread of HIV among injection drug users and others in the province.

NIDA Notes Category Graphic

Seek-Test-Treat-Retain To Stop the Spread of HIV

February 2013

Despite the advances in treatment and prevention, roughly 50,000 new HIV infections still occur annually in the Nation. Research, in large part supported by NIDA, has produced a strategy to address this circumstance and break the epidemiological impasse: seek out HIV-infected individuals, particularly those in “hard-to-reach” groups that have minimal contact with the health care system; offer them HIV testing and treatment; and provide support to help them stay in treatment.

NIDA Notes Category Graphic

Deadline Approaching: U.S.-Mexico Drug Abuse Prevention Research Fellowship

February 2013

Researchers interested in applying for the NIDA U.S.-Mexico Drug Abuse Prevention Research Fellowship need to submit application materials by April 1, 2013. 

NIDA Notes Category Graphic

Study Endorses Onsite HIV Testing Without Risk Reduction Counseling

April 2013

Patients were more likely to take a rapid HIV test when substance abuse treatment programs offered the test onsite rather than referred for offsite testing. Patients were equally likely to accept and learn their HIV status whether the offer of onsite testing was accompanied by 30 minutes of risk reduction counseling or by 5 minutes of brief information on the testing procedure. Onsite testing accompanied by brief information was cost effective, taking into account the projected lifetime costs of treatment and the gains in health and longevity for detected cases.

NIDA Notes Category Graphic

Dr. Marilyn Huestis Q & A: Matching Drug Effects to Drug Concentrations

September 2013

Dr. Marilyn Huestis of NIDA’s Intramural Research Program talks about conducting research on drug effects with human subjects, developing tests to help law enforcement identify drugged drivers, and an assay to help identify children whose prenatal exposure to anti-HIV drugs may put them at risk for adverse developmental outcomes.

NIDA Notes Category Graphic

HIV Infection Accelerates Hepatitis C–Related Liver Fibrosis

January 2014

Study patients with HIV­­–hepatitis C coinfection progressed to successive degrees of severity of liver fibrosis 9 years sooner than those infected with HCV alone. Further findings from the study suggest that suppressing HIV with antiretroviral medications may slow HCV-related liver fibrosis.

NIDA Notes Category Graphic

Study: Treat Jail Detainees’ Drug Abuse To Lower HIV Transmission

March 2014

Active drug use before incarceration was associated with decreased engagement in HIV treatment among HIV-infected jail detainees. The severity of drug dependence correlated with worsening measures of engagement in HIV treatment. The study concludes that evidence-based treatment for drug abuse in jails may result in improved HIV treatment outcomes, which in turn could help slow HIV-transmission rates in the United States.

NIDA Notes Category Graphic

Expanded HIV Screening Projected To Decrease Spread of the Virus

April 2014

Intensified screening for HIV among injection drug users receiving opioid agonist therapy could prevent more than twice as many new infections as current screening practice. A recent study based on mathematical modeling found that screening every 6 months instead of annually, and adding viral RNA testing to the currently used HIV antibody testing, could improve both effectiveness and cost-effectiveness.

Pages

NIDA Notes

Tags

Drug Topics

Drugs of Abuse

Population Groups

Related Topics